Drug intelligence / Profile preview

QSC303294

Development stage: Unknown
Lead developer: Bial
Administration: Oral

Overview

QSC303294 is an investigational drug candidate being developed by BIAL. It is currently in Phase I clinical development, with a completed study (ISRCTN16910437) conducted in the United Kingdom to evaluate the safety, tolerability, and pharmacokinetics of different formulations in healthy volunteers. Due to the early-stage nature of the program, the sponsor has deferred publication of the full trial details, meaning the specific therapeutic indication, molecular target, and chemical structure of the compound remain proprietary and are not yet publicly available.

Beyond the preview

Go deeper on QSC303294.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QSC303294.

Explore the full profile